- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01944397
A CALIBER Study: Risk Factors for Stroke, Heart Failure, and Myocardial Infarction in Atrial Fibrillation
Risk Factors for the Development of Stroke, Heart Failure, and Myocardial Infarction in Patients Diagnosed With Atrial Fibrillation: a CALIBER Study
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The development of stroke in AF patients continues to be an area of substantial research focus. However, comparatively little research has investigated the extent to which HF and MI also make a substantial contribution to morbidity and mortality in this patient group, and whether there is overlap in the prognostic factors associated development of stroke, HF, and MI.
Conen et al. demonstrated that mortality risk in AF patients is partly mediated by the development of non-fatal stroke, HF, and MI. However, they did not investigate differences in the cumulative incidence of these conditions between different patient groups (e.g. men and women), or the relationship between potential prognostic factors and the development of these conditions. Sets of prognostic factors for stroke and HF in AF patients have been defined through the development of prognostic models, but these models were developed specifically for each condition so it is unclear whether these prognostic factors are associated with increased risk of a particular condition, or simply any major adverse cardiovascular event. Additionally, some potentially important prognostic factors were not evaluated in these studies (e.g. anaemia and kidney failure).
Thus we chose to conduct an exploratory study of prognostic factors for HF, MI, and stroke in patients diagnosed with AF. We selected our candidate factors from those that have previously been associated with stroke, HF, or MI (in AF patients or the general population). Identification of prognostic factors for stroke, HF, and MI in those diagnosed with AF is a first step toward understanding both the development of these conditions, and the scope for targeting preventive treatments to improve prognosis.
This study will be undertaken using linked electronic health record data for primary and secondary care from CALIBER. This data set contains a broad range of clinically relevant, clinically conducted measurements of potential prognostic factors, and also provides a very large baseline sample from which we can draw a sufficient number of incident AF cases to investigate our three endpoints.
The study has two aims. First, to determine the cumulative incidence of fatal and non-fatal heart failure (HF), myocardial infarction (MI) and stroke (ischaemic, haemorrhagic, and NOS) in patients diagnosed with atrial fibrillation (AF). Differences between clinically relevant groups (e.g. men and women) will be explored. Second, to compare the direction and magnitude of associations between prognostic factors and the development of these conditions (HF, stroke, MI) in patients with AF. The following panels of prognostic factors will be investigated: sociodemographic; anthropomorphic and haemodynamic; behavioural; co-existing conditions (cardiovascular and non-cardiovascular); blood biomarkers; secondary preventive drugs.
This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the NIHR and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (GPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
London, Storbritannia, WC1E 7H
- University College London
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients with a coded diagnosis for atrial fibrillation in their primary or secondary care record.
- Patients in GPRD practices which are deemed "up to standard" by GPRD criteria
- Patients whose records are deemed "acceptable" by GPRD criteria and contain at least one year of data
- Patients whose age and sex, as recorded in GPRD is the same as that recorded in HES.
Exclusion Criteria:
- A diagnosis of heart failure, stroke, or myocardial infarction occurring before diagnosis of atrial fibrillation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Atrial fibrillation
Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Heart failure
Tidsramme: Throughout follow-up (maximum 12 years)
|
Throughout follow-up (maximum 12 years)
|
|
Myocardial infarction
Tidsramme: Throughout follow-up (maximum 12 years)
|
Throughout follow-up (maximum 12 years)
|
|
Stroke (ischaemic, haemorrhagic, and NOS)
Tidsramme: Throughout follow-up (maximum 12 years)
|
Throughout follow-up (maximum 12 years)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Non-cardiovascular mortality
Tidsramme: Throughout follow-up (maximum 12 years)
|
Throughout follow-up (maximum 12 years)
|
|
|
Cardiovascular mortality
Tidsramme: Throughout follow-up (maximum 12 years)
|
Excluding heart failure, myocardial infarction, stroke
|
Throughout follow-up (maximum 12 years)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Katherine I Morley, PhD, University College, London
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CALIBER-12-03-PROG-18
- RP-PG-0407-10314 (Annet stipend/finansieringsnummer: Wellcome Trust)
- 086091/Z/08/Z (Annet stipend/finansieringsnummer: Wellcome Trust)
- G0902393 (Annet stipend/finansieringsnummer: Medical Research Council (UK))
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hjerteinfarkt
-
First Affiliated Hospital of Ningbo UniversityPåmelding etter invitasjonSTEMI - ST-segment Elevation Myocardial InfarctionKina
-
Kitasato UniversityRekrutteringAterosklerose | Akutt koronarsyndrom | Stabil angina | Koronar; Iskemisk | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
University Hospital, Strasbourg, FranceAvsluttetST Elevatation Myocardial Infarction (STEMI)Frankrike
-
VesalioAktiv, ikke rekrutterendeSegment Elevation Myocardial Infarction (STEMI)Sveits
-
AstraZenecaFullførtHjerteinfarkt | Segment Elevation Myocardial Infarction (STEMI)Australia, Frankrike, Italia, Spania, Storbritannia, Sverige, Tyskland, Ungarn, Danmark, Østerrike, Canada, Nederland, Algerie
-
Central Hospital, Nancy, FranceHar ikke rekruttert ennåSTEMI - ST Elevation Myocardial Infarction (MI)
-
Assiut UniversityHar ikke rekruttert ennåSTEMI - ST Elevation Myocardial Infarction (MI) | Primær perkutan koronar intervensjon | LVOT VTIEgypt
-
Capital Medical UniversityFullførtTransradial Approach, Primær PCI, ST-segment Elevation Myocardial InfarctionKina
-
Implicit BioscienceWashington University School of Medicine; University of VirginiaAktiv, ikke rekrutterendeSTEMI | STEMI - ST Elevation Myocardial Infarction (MI) | Stentimplantasjon | STEMI (ST Elevation MI)Forente stater
-
University Hospital, MontpellierUniversity Hospital, NīmesFullførtNSTEMI | NSTE-ACS (NSTEMI og UA) | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionFrankrike